Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice

Journal of Huntington's Disease

Volumn 5, Issue 3, 2016, Pages 239-248

  Keeler, Allison M ^a   Sapp, Ellen ^b   Chase, Kathryn ^a   Sottosanti, Emily ^a   Danielson, Eric ^a   Pfister, Edith ^a   Stoica, Lorelei ^a   DiFiglia, Marian ^b   Aronin, Neil ^a   Sena Esteves, Miguel ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AAV; Htt; huntingtin; Huntington; in situ hybridization; microRNA; mRNA; RNAscope

Indexed keywords

GREEN FLUORESCENT PROTEIN; HUNTINGTIN; MESSENGER RNA; MICRORNA; MUTANT PROTEIN; PARVOVIRUS VECTOR; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; PHOSPHOPROTEIN DARPP 32; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; HUNTINGTON CHOREA; INTRASTRIATAL DRUG ADMINISTRATION; MEDIUM SPINY NEURON; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONTENT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; HUNTINGTON DISEASE; METABOLISM; NERVE CELL; PATHOLOGY; TRANSGENIC ANIMAL; TRINUCLEOTIDE REPEAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CALCIUM-BINDING PROTEINS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICRORNAS; NEURONS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TRINUCLEOTIDE REPEATS;

EID: 84990055836     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-160215     Document Type: Article

References (27)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971-83.
2. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-3.
3. Aronin N, DiFiglia M. Huntingtin-lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing. Mov Disord. 2014;29(11):1455-61.
4. Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012;18(7):1136-41.
5. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005-17.
6. Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C, et al. Adeno-associated virus-delivered artificial microRNAextends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79(4):687-700.
7. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10(8):816-20.
8. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102(16): 5820-5.
9. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, et al. Artificial miRNAs mitigate shRNAmediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105(15):5868-73.
10. Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, et al. Silencing mutant huntingtin by adenoassociated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther. 2014;25(5):461-74.
11. Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther. 2014;22(4):797-810.
12. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, ChesseletMF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11-26.
13. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, et al. Extensive early motor and nonmotor behavioral deficits are followed by striatal neuronalloss in knock-in Huntington's disease mice. Neuroscience. 2008;157(1):280-95.
14. Valencia A, Sapp E, Kimm JS, McClory H, Ansong KA, Yohrling G, et al. Striatal synaptosomes from Hdh140Q/140Q knock-in mice have altered protein levels, novel sites of methionine oxidation, and excess glutamate release after stimulation. J Huntingtons Dis. 2013;2(4): 459-75.
15. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther. 2008;16(5):947-56.
16. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17(6):1053-63.
17. Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. 2012;20(3):590-600.
18. Gao G, Alvira MR, Somanathan S, LuY, Vandenberghe LH, Rux JJ, et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A. 2003;100(10):6081-6.
19. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 1995;14(5):1075-81.
20. Wang G, Liu X, Gaertig MA, Li S, Li XJ. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113(12):3359-64.
21. Dueck H, Khaladkar M, Kim TK, Spaethling JM, Francis C, Suresh S, et al. Deep sequencing reveals cell-type-specific patterns of single-cell transcriptome variation. Genome Biol. 2015;16:122.
22. Wang N, Gray M, Lu XH, Cantle JP, Holley SM, Greiner E, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med. 2014;20(5):536-41.
23. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006;13(3): 528-37.
24. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci. 2007;27(37):9928-40.
25. Salegio EA, Samaranch L, Kells AP, Mittermeyer G, San Sebastian W, Zhou S, et al. Axonal transport of adenoassociated viral vectors is serotype-dependent. Gene Ther. 2013;20(3):348-52.
26. San SebastianW, Samaranch L, Heller G, Kells AP, Bringas J, Pivirotto P, et al. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther. 2013;20(12):1178-83.
27. Hadaczek P, Stanek L, Ciesielska A, SudhakarV, Samaranch L, Pivirotto P, et al. WidespreadAAV1-andAAV2-mediated transgene expression in the nonhuman primate brain: Implications for Huntington's disease. Mol Ther Methods Clin Dev. 2016;3:16037.